AbbVie Inc. vs PepsiCo, Inc.: Strategic Comparison

This in-depth comparison examines AbbVie Inc. and PepsiCo, Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AbbVie Inc. on its own, evaluating PepsiCo, Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AbbVie Inc. and PepsiCo, Inc. is widest.

On the headline numbers, AbbVie Inc. reports annual revenue of $61.2B against $93.9B for PepsiCo, Inc., while their respective market capitalizations stand at $451.5B and $205.0B. AbbVie Inc. is headquartered in United States and PepsiCo, Inc. operates from United States, and those different home markets shape how each company competes.

AbbVie Inc.: AbbVie began as the separated pharmaceutical arm of Abbott Laboratories and became one of the world's largest biopharma companies by using Humira cash flow to build a broader portfolio. The company now presents itself as a diversified specialty-medicine platform rather than a single-product story.

PepsiCo, Inc.: PepsiCo is often framed through the cola wars, but the Frito-Lay system is the real structural engine. The 1965 merger created a company that could negotiate with retailers using both snacks and beverages, turning distribution breadth into an economic moat.

AbbVie Inc. and PepsiCo, Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AbbVie Inc. and PepsiCo, Inc..

AbbVie Inc. business model: AbbVie earns revenue from patented and specialty medicines sold globally through healthcare systems, insurers, distributors, specialists, hospitals, and aesthetics providers. Immunology is the largest segment, supported by neuroscience, oncology, aesthetics, eye care, and other therapeutics.

PepsiCo, Inc. business model: PepsiCo makes money from convenient foods, beverages, concentrates, foodservice, licensing, and international packaged-food operations. The company sells finished products through company-owned and third-party distribution, and it benefits from direct-store-delivery strength in snacks and beverages.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AbbVie Inc. stack up against those of PepsiCo, Inc..

AbbVie Inc. competitive advantage: AbbVie's advantage comes from deep immunology scale, specialist sales relationships, strong cash flow, global clinical and regulatory capabilities, and a portfolio led by Skyrizi, Rinvoq, Botox, Vraylar, Imbruvica, Venclexta, and Elahere.

PepsiCo, Inc. competitive advantage: PepsiCo advantage comes from the combination of Frito-Lay scale, beverage brands, global distribution, direct-store delivery, product breadth, retailer relationships, and marketing investment.

Future prospects matter as much as current results. The growth strategies below explain how AbbVie Inc. and PepsiCo, Inc. each plan to expand from here.

AbbVie Inc. growth strategy: AbbVie's growth strategy is to expand indications for Skyrizi and Rinvoq, defend Botox and aesthetics, invest in neuroscience and oncology, use targeted acquisitions to add late-stage assets, and maintain disciplined cash generation after Humira's decline.

PepsiCo, Inc. growth strategy: PepsiCo strategy centers on international growth, productivity, brand restages, zero-sugar beverages, functional hydration, convenient foods, and portfolio renovation. Steve Schmitt became CFO effective November 10, 2025, adding new finance leadership for the next phase of cost discipline.

A closer look at the financial trajectory of AbbVie Inc. and PepsiCo, Inc. rounds out the comparison.

AbbVie Inc.: AbbVie generated $61.160 billion in FY2025 net revenue, up 8.6% on a reported basis, with immunology contributing $30.406 billion. Q1 2026 revenue reached $15.002 billion, showing continued growth after the Humira patent cliff as Skyrizi and Rinvoq scaled.

PepsiCo, Inc.: PepsiCo reported $93.925 billion of FY2025 net revenue, up from $91.854 billion in FY2024 and $91.471 billion in FY2023. FY2025 net income attributable to PepsiCo was $8.240 billion. PepsiCo employed approximately 306,000 people worldwide as of December 27, 2025.